Why CymaBay, With 159% Growth This Year, Just Surged For A Second Day Running

Shares of CBAY stock surged for a second day Friday as analysts compared CymaBay Therapeutics' (CBAY) experimental liver-disease treatment to rivals from Intercept Pharmaceuticals (ICPT) and Genfit (GNFT). The company tested its drug in patients with primary biliary cholangitis, a chronic…#cbay #cymabaytherapeutics #cymabay #intercept #ocaliva #genfit #leerinkpartners #thomassmith #bullishly #notably
Source: Reuters: Health - Category: Consumer Health News Source Type: news